Buy CRDF by Dec 9, 2026.

If you like micro-cap biotech plays with awesome potential driven by Ph 3 trial catalysts, CRDF (Cardiff Oncology) is worth adding to your watchlist. They are targeting a huge, underserved market -- first-line RAS-mutated metastatic colorectal cancer (mCRC)... and recent readouts suggest their drug drastically beats standard-of-care and they call it "onvansertib". They just completed a successful End of Ph 2 meeting with FDA. Phase 3 is targeted for Q1 2027. Cash Balance: \~$34.5M at Q2 2026, plus an extra …